ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, June 2000, p. 1731–1733 0066-4804/00/$04.00⫹0 Copyright © 2000, American Society for Microbiology. All Rights Reserved.
Vol. 44, No. 6
Quinolone Resistance in Enterotoxigenic Escherichia coli Causing Diarrhea in Travelers to India in Comparison with Other Geographical Areas JORDI VILA,1* MARTHA VARGAS,1 JOAQUIM RUIZ,1 MANUEL CORACHAN,2 M. TERESA JIMENEZ DE ANTA,1 AND JOAQUIM GASCON2 Departments of Microbiology1 and Infectious Diseases (Tropical Medicine Unit),2 IDIBAPS (Institut d’Investigacions Biome`diques August Pı´ i Sunyer), Hospital Clı´nic, School of Medicine, University of Barcelona, Barcelona, Spain Received 30 December 1998/Returned for modification 18 September 1999/Accepted 27 March 2000
Enterotoxigenic Escherichia coli isolates were identified as a cause of traveler’s diarrhea in 82 of 520 (16%) patients and tested for resistance to seven antimicrobial agents. Thirty patients (36%) needed antimicrobial therapy: 17 (56%) for persistence of symptoms and 13 (44%) for severity of symptoms. Ampicillin, tetracycline, and trimethoprim-sulfamethoxazole resistance was high. Chloramphenicol showed moderate activity, and amoxicillin plus clavulanic acid, nalidixic acid, and ciprofloxacin showed very good activity. Five nalidixic acid-resistant strains were isolated, four from patients visiting India. Enterotoxigenic Escherichia coli (ETEC) is the major cause of traveler’s diarrhea in people from industrialized countries visiting less-developed countries (6, 7) and is an important cause of dehydrating diarrhea in infants and children in lessdeveloped countries (13). Traveler’s diarrhea caused by ETEC strains is usually a mild, self-limited disease, but for severe traveler’s diarrhea, early treatment with loperamide and an antibiotic such as trimethoprim-sulfamethoxazole, doxycycline, or a fluoroquinolone has been recommended (4). Many previous studies of antimicrobial susceptibility of ETEC involved a small number of isolates from a single geographic location. We, therefore, performed antimicrobial susceptibility testing of ETEC isolates causing traveler’s diarrhea originating from diverse geographical locations. Investigation of the mechanisms of acquisition of quinolone resistance in the nalidixic acid-resistant ETEC strains was also performed. During the period from 1994 to 1997, stool specimens from 520 adult patients with traveler’s diarrhea were analyzed. The patients were recruited from the traveler’s clinic of the Tropical Medicine Department of the Hospital Clinic. All patients had diarrhea on arrival in Spain or within 2 days after their return. The stool specimens were cultured for E. coli and other bacterial enteropathogens by conventional methods (11). Single-colony subcultures of all different lactose-fermenting colonial morphotypes growing on MacConkey agar were identified by conventional criteria. The E. coli isolates were tested by PCR to detect the heat-stable (ST) and heat-labile (LT) toxin genes (15). ETEC strains were isolated from 82 patients (16%) with traveler’s diarrhea. The distribution of these strains according to the type of enterotoxin synthesized was as follows: 58 strains (71%) produced the ST, 11 strains (13%) produced LT, and 13 strains (16%) produced both toxins (LT/ST). ETEC strains were isolated from stool samples of patients traveling to different tropical and subtropical areas, except for Central and South Africa. The range of prevalence was from 7.5% to 31%, with West Africa and the Indian Subcontinent being the two geographic areas where ETEC strains were more
prevalent, at 31 and 22%, respectively. Thirty patients (36%) needed antimicrobial therapy: 17 patients (56%) because of persistence of symptoms and 13 (44%) because of severity of symptoms. In 14 treated patients, the cause of diarrhea was ST-producing ETEC (ETEC-ST), representing 24% of the total number of strains of ETEC-ST, whereas in 7 (63%) and 9 (69%) patients, the cause was LT- and LT/ST-producing ETEC, respectively (P ⬍ 0.02). All patients were empirically treated with ciprofloxacin, and in all, the duration of diarrhea was shortened and the accompanying symptoms such as abdominal discomfort, flatulence, nausea, and vomiting were relieved. It is noteworthy that patients with ETEC-LT and ETEC-LT/ST strains required antimicrobial therapy more frequently than patients with ETEC-ST strains. However, this finding needs to be confirmed in future studies. The MICs for the clinical isolates studied were determined by E-test according to standard practice. E. coli ATCC 25922 was used as a reference strain for quality control. The breakpoints considered to define a resistant strain were those recommended in reference 12. The MICs of antimicrobial agents for ETEC-ST, ETEC-LT, and ETEC-ST/LT strains are shown in Table 1. Randomized, controlled studies have demonstrated that a 3- to 5-day course of an antibiotic can reduce the duration of an acute diarrheal episode in travelers. Most studies done during the 1980s with tetracycline (8) or with trimethoprim alone (1) or in combination with sulfamethoxazole (1, 2) showed the effectiveness of these antimicrobial agents in the treatment of acute diarrhea caused by ETEC, shortening the duration of excretion of microorganisms, resulting in earlier termination of illness. However, the emergence and dissemination of resistance to cotrimoxazole in fecal E. coli were observed during oral administration of this agent (9). Resistance to cotrimoxazole and tetracycline is now present in ⬎50% of ETEC strains isolated from tropical and subtropical countries (Table 1) (10). This fact is due to the extensive use of these antimicrobial agents in these countries (10) and precludes their empirical use for the treatment of traveler’s diarrhea. Among the other antimicrobial agents tested in this study, ampicillin was moderately effective. Chloramphenicol presented good activity against ETEC, but quinolones such as nalidixic acid or ciprofloxacin and amoxicillin plus clavulanic acid showed the best activity against these microorganisms. In
* Corresponding author. Mailing address: Laboratori de Microbiologia, Hospital Clı´nic, Facultat de Medicina, Universitat de Barcelona, Villarroel, 170, 08036 Barcelona, Spain. Phone: 34.3.2275522. Fax: 34.3.2275454. E-mail:
[email protected]. 1731
ANTIMICROB. AGENTS CHEMOTHER.
46 100 73 100 91 37 27
MIC (g/ml)
a
MIC50 and MIC90, MICs at which 50 and 90% of the isolates tested are inhibited, respectively. % Susceptible, percentage of strains susceptible to the breakpoint concentration.
256 3 256 0.016 12 256 32 256 3 4 0.012 3 256 32 77 100 77 100 92 54 85 256 4 256 0.016 3 256 32 2 3 4 0.012 3 4 0.047 55 100 83 98 95 42 47 256 6 256 0.023 6 256 32
MIC90 MIC50
4 3 4 0.012 3 256 32 Ampicillin Amoxicillin-clavulanic acid Chloramphenicol Ciprofloxacin Nalidixic acid Tetracycline Trimethoprim-sulfamethoxazole
MIC90 MIC50
MIC90
% Susceptible ETEC-ST/LT (n ⫽ 13)
% Susceptible ETEC-ST (n ⫽ 58) Antibiotic
Result for strainsa
TABLE 2. Mutations in the gyrA and parC genes of quinoloneresistant clinical isolates of ETEC
Strain
MIC50
ETEC-LT (n ⫽ 11)
% Susceptible
NOTES
TABLE 1. MICs of seven antimicrobial agents for 82 ETEC clinical isolates
1732
Wild type 135-ST 265-ST 12-ST 225-ST/LT 299-LT
Ciprofloxacin
Nalidixic acid
0.032 0.25 32 0.19 0.19
32 256 ⬎256 256 256
Amino acid change GyrA
ParC
Position 83
Position 87
Position 80
Position 84
Ser Ala Leu Leu Leu Leu
Asp
Ser
Glu
Asn
Ile
Gly
the last decade, fluoroquinolones have been shown to be highly effective in reducing the duration of traveler’s diarrhea (3, 5, 14, 18). However, 5 (6%) of the 82 ETEC strains investigated in our study were resistant to nalidixic acid, and one of them was also resistant to ciprofloxacin (MIC of 32 g/ml). The quinolone resistance in E. coli has mainly been associated with mutations in the gyrA and parC genes (16, 17). All nalidixic acid-resistant ETEC strains were analyzed for mutations in the gyrA and/or parC genes by PCR and DNA sequencing of the quinolone resistance-determining region as described in references 16 and 17 (Table 2). One ETEC-ST strain for which the MICs were 32 (nalidixic acid) and 0.032 (ciprofloxacin) g/ml had a substitution in Ser-83 of the GyrA protein to Ala. Three strains (one each of ST, LT, and ST/LT) for which the MIC of nalidixic acid was 256 g/ml and that of ciprofloxacin was between 0.19 and 0.25 g/ml showed a substitution of Ser-83 by Leu. These results confirm that a substitution at Ser-83 is sufficient to confer a very high nalidixic acid resistance level. Finally, one strain for which the MIC of ciprofloxacin was 32 g/ml and that of nalidixic acid was ⬎256 g/ml showed three mutations—two in the gyrA gene, which generated substitutions of Ser-83 to Leu and Asp-87 to Asn, and the third in the parC gene, producing a change in Ser-80 to Ile. In E. coli, a higher quinolone resistance level has been related to the presence of concomitant mutations in the gyrA and parC genes (16, 17). Of the five nalidixic-acid resistant ETEC strains isolated, four (17%) were isolated from patients who had traveled to India. Nalidixic acid was introduced a few years ago as the first-line therapy for shigellosis in some areas of this country, and therefore ETEC strains resistant to nalidixic acid are now emerging. In summary, ETEC strains, and in particular ETEC-LT strains, are a frequent cause of traveler’s diarrhea requiring antimicrobial therapy. The resistance of these microorganisms to the classical agents such as cotrimoxazole, tetracycline, and ampicillin is very high due to the widespread use of these antimicrobial agents in tropical and subtropical countries. Fluoroquinolones are drugs of choice for most adults traveling to high-risk parts of the world. Although the level of resistance to nalidixic acid is generally low, in some geographical areas such as India, it is a matter for concern. Strains for which the MICs of nalidixic acid are high are likely to have at least one mutation of the gyrA gene. The induction of further mutations, e.g., by exposing such strains to fluoroquinolones, is likely to result in a significantly reduced susceptibility to fluoroquinolones. These agents should therefore be used with caution. Furthermore, it is important to continue the surveillance of quinolone resistance levels in these microorganisms.
VOL. 44, 2000
NOTES
This work was supported in part by grant SAF97/0091 from the Comisio ´n Interministerial de Ciencia y Tecnologı´a, Plan Nacional I⫹D. REFERENCES 1. Black, R. E., M. M. Levine, M. L. Clements, L. Cisneros, and V. Daya. 1982. Treatment of experimental induced enterotoxigenic Escherichia coli diarrhea with trimethoprim, trimethoprim-sulfamethoxazole, or placebo. Rev. Infect. Dis. 4:540–545. 2. DuPont, H. L., R. R. Reves, E. Galindo, P. S. Sullivan, L. V. Wood, and J. G. Mediola. 1982. Treatment of travelers’ diarrhea with trimethoprim/sulfamethoxazole and with trimethoprim alone. N. Engl. J. Med. 307:841–844. 3. DuPont, H. L., C. D. Ericsson, J. J. Mathewson, and M. W. DuPont. 1992. Five versus three days of ofloxacin therapy for travelers’ diarrhea: a placebo controlled study. Antimicrob. Agents Chemother. 36:87–91. 4. DuPont, H. L., and C. D. Ericsson. 1993. Prevention and treatment of traveler’s diarrhea. N. Engl. J. Med. 328:1821–1826. 5. Ericsson, C. D., P. C. Johnson, H. L. DuPont, D. R. Morgan, J. A. Bitsura, and F. J. Cabada. 1987. Ciprofloxacin or trimethoprim-sulfamethoxazole as initial therapy for traveler’s diarrhea. Ann. Intern. Med. 106:216–220. 6. Gasco ´n, J., J. Vila, M. E. Valls, L. Ruiz, J. Vidal, M. Corachan, G. Prats, and M. T. Jimenez de Anta. 1993. Etiology of traveler’s diarrhea in Spanish travelers to developing countries. Eur. J. Epidemiol. 9:217–223. 7. Gorbach, S. L., B. H. Kean, D. G. Evans, D. J. Evans, Jr., and D. Bessudo. 1975. Traveler’s diarrhea and toxigenic Escherichia coli. N. Engl. J. Med. 292:933–936. 8. Merson, M. H., R. B. Sack, S. Islam, G. Saklayen, N. Huda, I. Huq, A. W. Zulich, R. H. Yolken, and A. Z. Kapikian. 1980. Disease due to enterotoxigenic Escherichia coli in Bangladeshi adults: clinical aspects in a controlled trial of tetracycline. J. Infect. Dis. 141:702–711. 9. Murray, B. E., E. R. Rensimer, and H. L. DuPont. 1982. Emergence of
10. 11. 12.
13. 14.
15. 16.
17. 18.
1733
high-level trimethoprim resistance in fecal Escherichia coli during oral administration of trimethoprim or trimethoprim-sulfamethoxazole. N. Engl. J. Med. 306:130–135. Murray, B. E. 1986. Resistance of Shigella, Salmonella, and other selected enteric pathogens to antimicrobial agents. Rev. Infect. Dis. 8:S172–S181. Murray, P. R., E. J. Baron, M. A. Pfaller, F. C. Tenover, and R. H. Yolken (ed.). 1995. Manual of clinical microbiology, 6th ed. ASM Press, Washington, D.C. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 2nd ed. Approved standard M7-A2. National Committee for Clinical Laboratory Standards, Wayne, Pa. Sack, R. B. 1975. Human diarrheal disease caused by enterotoxigenic Escherichia coli. Annu. Rev. Microbiol. 29:333–353. Taylor, D. N., J. L. Sanchez, W. Candler, S. Thornton, C. McQueen, and P. Echevarria. 1991. Treatment of travelers’ diarrhea: ciprofloxacin plus loperamide compared with ciprofloxacin alone. A placebo-controlled, randomized trial. Ann. Intern. Med. 114:731–734. Vargas, M., J. Gasco ´n, F. Gallardo, M. T. Jimenez de Anta, and J. Vila. 1999. Prevalence of diarrheagenic Escherichia coli strains detected by PCR in patients with traveler’s diarrhea. Clin. Microbiol. Infect. 4:682–688. Vila, J., J. Ruiz, F. Marco, A. Barcelo, P. Gon ˜ i, E. Giralt, and T. Jimenez de Anta. 1994. Association between double mutation in gyrA gene of ciprofloxacin-resistant clinical isolates of Escherichia coli and MICs. Antimicrob. Agents Chemother. 38:2477–2479. Vila, J., J. Ruiz, P. Gon ˜ i, and M. T. Jimenez de Anta. 1996. Detection of mutations in parC in quinolone-resistant clinical isolates of Escherichia coli. Antimicrob. Agents Chemother. 40:491–493. Wistrom, J., M. Jertborn, S. A. Hedstrom, K. Alestig, G. Englund, B. Jellheden, and S. R. Norrby. 1989. Short-term self-treatment of travelers’ diarrhea with norfloxacin: a placebo controlled study. J. Antimicrob. Chemother. 23:905–913.
